Tissue engineering and cell therapy comprise a market for regenerative products that is expected to grow in the United States from $6.9 billion in 2009 to almost $32 billion by 2018. This market spans many specialties, the biggest of which is therapies for degenerative and traumatic orthopedic and spine applications. Other disorders that will benefit from cell therapies include cardiac and vascular disease, a wide range of neurological disorders, diabetes, inflammatory diseases, and dental decay injury. Key factors expected to influence the market for regenerative medicine are continued political actions, government funding, clinical trials results, industry investments, and an increasing awareness among both physicians and the general public of the accessibility of cell therapies for medical applications.
"We have witnessed, in the span of only about five years, a ten-fold increase in the market for products in cell therapy and tissue engineering, and this rate of growth does not appear to be abating, despite economic challenges, healthcare reform or even typical market dynamics," says Patrick Driscoll, President of MedMarket Diligence and publisher of the 2010 report on tissue engineering and cell therapy. The reasons are many, says Driscoll, including that the range of applications of cell therapy and tissue engineering is very broad (encompassing nearly all clinical fields), the clinical benefits are readily demonstrable compared with existing therapies (and in some conditions there are no effective alternatives)
The foundations of the market have been in the initial adoption of orthopedic and skin grafts from autologous and allograft sources. This routine use of cell and tissue material has facilitated the progressive market adoption of cells and tissues from more complex sources including a wide range of stem cell types, from adult, embryonic and other pluripotent types. Another major technology thrust that has been well accepted already and will therefore facility future market growth is the use of extracellular matrices that provide scaffolding structures and physiologic environments stimulating tissue growth and repair. While this latter technology, too, has roots in orthopedics, the technology is evolving on separate paths for applications in cardiology, urology and other clinical areas.
Clinical applications in cell therapy and tissue engineering now encompass current and emerging markets including cardiology, neurology, urology, skin/integumentary, orthopedics/
The MedMarket Diligence Report, “Tissue Engineering, Cell Therapy and Transplantation:
The report provides market size and share data, with forecast market data to 2018, for the U.S., Europe, Asia/Pacific and Rest of World.
The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast and assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.
The report is described in detail, with table of contents and list of exhibits at http://mediligence.com/
